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Response to Aubin et al 
Aubin and colleagues argue that in our article we have produced misleading claims regarding estimated 
risk reduction from switching from conventional cigarettes to e-cigarettes because duration of exposure 
is more important than degree of exposure in raising cancer risk. We acknowledge that assessing whether 
e-cigarette use actually reduces harm among conventional cigarette smokers is challenging and that the 
adverse health effects of tobacco are related to duration of use, not just exposure. However, both are 
essential causal factors and to the extent that risk is broadly proportionate to either, a reduction in degree 
or duration of exposure will yield a proportionate reduction in risk. This is borne out by the evidence. 
Epidemiological studies directly support a link between the degree of exposure to nitrosamines, and 
other tobacco-specific toxicants assessed in our study, with subsequent cancer risk in conventional 
cigarette smokers (1) as well as lifelong never smokers (2). Based on this evidence, it’s likely that 
significantly reduced exposure in e-cigarette compared with cigarette users results in reduced cancer risk. 
Aubin et al further argue that nicotine can have adverse effects. While it is important to acknowledge 
that nicotine is not risk-free, particularly for vulnerable populations, including pregnant women and 
adolescents, post-marketing surveillance of licensed nicotine products and the epidemiological evidence 
from adult users of snus (a form of smokeless tobacco that is low in carcinogens but high in nicotine) in 
Sweden indicate that such effects are small relative to other constituents of tobacco smoke (3). 
Crucially, in the context of harm reduction it is important to quantify and compare risks. E-cigarette use 
can be expected to carry some risk, so adult conventional cigarette smokers who switch completely to e-
cigarettes instead of quitting smoking without the aid of such a device will be worse off than they would 
have been. However, smokers who switch to e-cigarette use who would otherwise have carried on 
smoking will benefit from a reduction in risk. Thus, a key determinant of whether e-cigarette use 
produces a public health gain is whether it causes more people to stop smoking than would otherwise 
have been the case, while not leading to initiation of either product among never users, particularly youth 
(4). The only population level estimate undertaken thus far has been in England, and it used time series 
analysis to estimate an additional 20,000 ex-smokers per year linked temporally with the increase in 
prevalence of e-cigarette use (5). 
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